Uncategorized
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot. read more
Garmin’s Strong Auto, Outdoor Growth Drives Analyst Rating, Despite Softer Fitness, Marine Sales
A KeyBanc analyst reiterates Sector Weight rating on Garmin. Q1 revenue up 11%, but EPS missed estimates. Fiscal 2025 outlook raised. Latest Ratings for GRMN Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 Deutsche Bank Upgrades Hold Buy Oct 2021 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for GRMN…
